UK alleges GSK paid off competitors to delay drugs

by Danica Kirka

Britain's competition watchdog accused GlaxoSmithKline on Friday of paying off competitors to delay launches of their own versions of GSK's best-selling antidepressant, Seroxat.

The Office of Fair Trading alleges made deals that infringed competition law with Alpharma Ltd., Generics (UK) Ltd and Norton Healthcare Ltd. over the supply of paroxetine, which GSK sold under the name Seroxat. The watchdog said GSK's conduct amounted to an abuse of its in the same market.

"The introduction of can lead to strong competition on price, which can drive savings for the (), to the benefit of patients and, ultimately, taxpayers," said Ann Pope, the senior director of services, infrastructure and public markets at the OFT. "It is therefore particularly important that the OFT fully investigates concerns that independent generic entry may have been delayed in this case."

The OFT alleges that when the generic drug companies tried to compete with Seroxat, GSK challenged them with allegations that their products would infringe upon GSK patents. To settle the disputes, the generic companies would receive payment from GSK, the OFT claimed.

The drug company said in a statement that it would fully cooperate with the investigation, which it said stemmed from activities that occurred between 2001 and 2004.

The company also said that the inquiry examines issues investigated by two European Commission inquiries, neither of which resulted in sanction.

" supports fair competition and we very strongly believe that we acted within the law," the statement said.

The company said it had noted the OFT's plan to issue what is known as a Statement of Objections.

Pope said the OFT would carefully consider what the companies said in response to their accusations before deciding whether they should be sanctioned. If The OFT decides the "pay for delay" agreements were unacceptable, it can impose fines of up to 30 percent of revenue over the timeframe in which the violations occurred.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Drug firm GSK fined $2.6 million for collusion

Oct 24, 2011

South Korea's anti-trust agency has fined drugmaker GlaxoSmithKline three billion won ($2.6 million) for conspiring with a Seoul rival over the sale of drugs, an official said Monday.

GSK unveils expansion plans in India, Nigeria

Nov 26, 2012

British drugmaker GlaxoSmithKline said it intends to increase its holdings in its Indian and Nigerian divisions, as part of a long-term strategy to expand into emerging markets, in a statement on Monday.

Recommended for you

Powdered measles vaccine found safe in early clinical trials

15 hours ago

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

Health care M&A leads global deal surge

Nov 23, 2014

In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

rsklyar
1 / 5 (1) Apr 29, 2013
How British swindlers are stealing in their cheating journal Nature Materials at https://connect.i...sr/blogs (Impertinent cheating ... & A robbery ...)

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.